Epigenetic Metal‐Organic Framework Nanoagonist Overcomes Triple Defenses to Enable Effective Chemo‐Metalloimmunotherapy in Platinum‐Resistant Ovarian Cancer
Advanced Materials · 2026-03 · 38 (14)
DOI: 10.1002/adma.202517286 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Materials, online erschienen am 03.02.2026. Verfasst von Ling Lin und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine, Dongguan Institute of Clinical Cancer Research, The Tenth Affiliated Hospital, Southern Medical University (Donggu…. Hauptthemen laut MEDLINE: Ovarian Neoplasms, Drug Resistance, Neoplasm, Immunotherapy, Epigenesis, Genetic. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 50 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Guangdong Basic and Applied Basic Research Foundation, Social Science and Technology Development Key Project of Dongguan.
Abstract (Originalsprache)
Platinum‐resistant ovarian cancer (PROC) responds poorly to platinum chemotherapy and evades immune surveillance by suppressing the cGAS‐STING pathway, leading to poor outcomes. Herein, we developed an epigenetic metal‐organic framework (MOF) nanoagonist (CMZ‐Pt‐SA@HA) that overcomes cisplatin (CisPt) resistance while restoring immune activation. The platform consists of Mn‐ZIF‐8 encapsulating CaO 2 and co‐loaded with CisPt and SAHA (a histone deacetylase inhibitor), then modified with hyaluronic acid to enable tumor targeting and controlled release. CMZ‐Pt‐SA@HA is multifunctional: SAHA downregulates resistance proteins epigenetically, CaO 2 triggers calcium overload and oxygen release, and Mn 2+ /Zn 2+ enhances oxidative stress and STING signaling, collectively strengthening chemo‐metalloimmunotherapy. These mechanisms intensify CisPt‐induced DNA damage and stimulate immune activation. CMZ‐Pt‐SA@HA applies a three‐step “POP” strategy to overcome PROC's triple defenses: (I) Pre‐targeting to enhance DNA‐CisPt adducts; (II) On‐targeting to block DNA repair; and (III) Post‐targeting to induce apoptosis by relieving hypoxia, arresting the cell cycle, damaging mitochondria, and activating cGAS‐STING. Whether used alone in subcutaneous tumors in preclinical ID8 and patient‐derived xenograft mouse models, or combined with anti‐PD‐L1 therapy in ascites metastasis models, CMZ‐Pt‐SA@HA consistently showed strong therapeutic efficacy. Its Mn 2+ ‐based magnetic resonance imaging (MRI) capability further supports image‐guided therapy and clinical translation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Laboratory Medicine, Dongguan Institute of Clinical Cancer Research, The Tenth Affiliated Hospital, Southern Medical University (Dongguan People's Hospital), Dongguan, P. R. China.
- Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, P. R. China.
- Department of Hepatobiliary Surgery, The Tenth Affiliated Hospital, Southern Medical University (Dongguan People's Hospital), Dongguan, P. R. China.
- Department of Pharmacy and Pharmaceutic Sciences, Faculty of Science, National University of Singapore, Singapore, Singapore.
- Dongguan Key Laboratory of Innovative Molecular Imaging, Dongguan People's Hospital, Dongguan, P. R. China.
ORCID-Profile: Zhiqiang Yu
Förderung
- National Natural Science Foundation of China
- Guangdong Basic and Applied Basic Research Foundation
- Social Science and Technology Development Key Project of Dongguan
- Dongguan Science and Technology of Social Development Program
- Basic and Applied Basic Research Foundation of Guangdong Province
Zitieren
APA
Lin, L., Zhang, Q., Liu, X., Yang, S., Fang, F., Zhang, X., Yang, Y., Zhang, W., Zhang, B., Zhao, Z., & Yu, Z. (2026). Epigenetic Metal‐Organic Framework Nanoagonist Overcomes Triple Defenses to Enable Effective Chemo‐Metalloimmunotherapy in Platinum‐Resistant Ovarian Cancer. Advanced Materials, 38(14). https://doi.org/10.1002/adma.202517286
Vancouver
Lin L, Zhang Q, Liu X, Yang S, Fang F, Zhang X, et al. Epigenetic Metal‐Organic Framework Nanoagonist Overcomes Triple Defenses to Enable Effective Chemo‐Metalloimmunotherapy in Platinum‐Resistant Ovarian Cancer. Advanced Materials. 2026;38(14). doi:10.1002/adma.202517286
BibTeX
@article{Lin2026,
author = {Lin, Ling and Zhang, Qiaoling and Liu, Xue and Yang, Siyi and Fang, Feng and Zhang, Xuanbo and Yang, Yuanyuan and Zhang, Wenjia and Zhang, Bingchen and Zhao, Zhihao and Yu, Zhiqiang},
title = {Epigenetic Metal‐Organic Framework Nanoagonist Overcomes Triple Defenses to Enable Effective Chemo‐Metalloimmunotherapy in Platinum‐Resistant Ovarian Cancer},
journal = {Advanced Materials},
year = {2026},
volume = {38},
number = {14},
doi = {10.1002/adma.202517286}
}
EUVIMED